Some cutting from the dishman carbogen con-call on vitamin D business.They are into it big time and a new capacity will be on board this fiscal.But they say its more artificial manipulation which chinese companies are doing.
Question --> On the marketable molecule side of the business, we were into Calciferol some years back and
now because of the imminent shortages, there has been massive price increase and some of our
competitors are now benefiting. So, are there any plans or is it possible for us to get into
Calciferol now?
Mark Griffiths: That is one of the focus areas, as Arpit mentioned about the Soft Gel facility. So, that is part of
the strategy to leverage some of those. It is one of the reasons why the Netherlands business has
been doing so well.
Question --> Mark, that would be Calciferol, right?
Mark Griffiths: Calciferol, Calcitriol, Alfacalcidol, there is a whole bunch of this, probably 20 different analogs
of Vitamin D.
Question --> By the end of this fiscal year, do we expect to get our facility on track?
Mark Griffiths: Soft Gel, yes. The facility is due to be operational by the end of this fiscal year
Actually the Cholecalciferol market, the shortage was already seen by us two years ago. The
Chinese manufacturers create an artificial shortage in the market and we were in this
Cholecalciferol business before and that is exactly what was causing us difficulties. The
profitability of the Netherlands facility improved because of the change in strategy. So, this is
an opportunity for us in terms of going in the market and then again convincing more customers
by highlighting our engagements with the previous customers, ongoing customers now and how
they are benefiting from the contract.